CN102369023A - 寡糖-蛋白缀合物 - Google Patents

寡糖-蛋白缀合物 Download PDF

Info

Publication number
CN102369023A
CN102369023A CN200980156896XA CN200980156896A CN102369023A CN 102369023 A CN102369023 A CN 102369023A CN 200980156896X A CN200980156896X A CN 200980156896XA CN 200980156896 A CN200980156896 A CN 200980156896A CN 102369023 A CN102369023 A CN 102369023A
Authority
CN
China
Prior art keywords
oligosaccharide
mixture
protein
mmol
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200980156896XA
Other languages
English (en)
Chinese (zh)
Inventor
C·潘
P·A·科诺维兹
L·Z·阿维拉
J·E·斯特法诺
M·R·里尔登
J·哈拉西
周群
L·扬
P·芬
郑晓阳
R·J·米勒
J·库茨科
朱云翔
D·帕特森
A·皮尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Priority to CN202011434866.5A priority Critical patent/CN112618724A/zh
Priority to CN201610298866.4A priority patent/CN105879047A/zh
Priority to CN202011052459.8A priority patent/CN112220930A/zh
Publication of CN102369023A publication Critical patent/CN102369023A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
CN200980156896XA 2008-12-16 2009-12-11 寡糖-蛋白缀合物 Pending CN102369023A (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202011434866.5A CN112618724A (zh) 2008-12-16 2009-12-11 寡糖-蛋白缀合物
CN201610298866.4A CN105879047A (zh) 2008-12-16 2009-12-11 寡糖-蛋白缀合物
CN202011052459.8A CN112220930A (zh) 2008-12-16 2009-12-11 寡糖-蛋白缀合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12285108P 2008-12-16 2008-12-16
US61/122,851 2008-12-16
PCT/US2009/067775 WO2010075010A2 (en) 2008-12-16 2009-12-11 Oligosaccharide-protein conjugates

Related Child Applications (4)

Application Number Title Priority Date Filing Date
CN2013103303923A Division CN103432566A (zh) 2008-12-16 2009-12-11 寡糖-蛋白缀合物
CN201610298866.4A Division CN105879047A (zh) 2008-12-16 2009-12-11 寡糖-蛋白缀合物
CN202011434866.5A Division CN112618724A (zh) 2008-12-16 2009-12-11 寡糖-蛋白缀合物
CN202011052459.8A Division CN112220930A (zh) 2008-12-16 2009-12-11 寡糖-蛋白缀合物

Publications (1)

Publication Number Publication Date
CN102369023A true CN102369023A (zh) 2012-03-07

Family

ID=42138937

Family Applications (5)

Application Number Title Priority Date Filing Date
CN202011434866.5A Pending CN112618724A (zh) 2008-12-16 2009-12-11 寡糖-蛋白缀合物
CN2013103303923A Withdrawn CN103432566A (zh) 2008-12-16 2009-12-11 寡糖-蛋白缀合物
CN201610298866.4A Pending CN105879047A (zh) 2008-12-16 2009-12-11 寡糖-蛋白缀合物
CN202011052459.8A Pending CN112220930A (zh) 2008-12-16 2009-12-11 寡糖-蛋白缀合物
CN200980156896XA Pending CN102369023A (zh) 2008-12-16 2009-12-11 寡糖-蛋白缀合物

Family Applications Before (4)

Application Number Title Priority Date Filing Date
CN202011434866.5A Pending CN112618724A (zh) 2008-12-16 2009-12-11 寡糖-蛋白缀合物
CN2013103303923A Withdrawn CN103432566A (zh) 2008-12-16 2009-12-11 寡糖-蛋白缀合物
CN201610298866.4A Pending CN105879047A (zh) 2008-12-16 2009-12-11 寡糖-蛋白缀合物
CN202011052459.8A Pending CN112220930A (zh) 2008-12-16 2009-12-11 寡糖-蛋白缀合物

Country Status (20)

Country Link
US (5) US8835614B2 (enExample)
EP (5) EP2465542B1 (enExample)
JP (6) JP5658167B2 (enExample)
CN (5) CN112618724A (enExample)
BR (2) BR122020010601B8 (enExample)
CA (2) CA3040973A1 (enExample)
CY (1) CY1121860T1 (enExample)
DK (3) DK2889043T3 (enExample)
ES (3) ES2937017T3 (enExample)
HR (2) HRP20150340T1 (enExample)
HU (2) HUE044381T2 (enExample)
IL (5) IL213595B (enExample)
LT (1) LT2889043T (enExample)
MX (3) MX364498B (enExample)
PL (2) PL2889043T3 (enExample)
PT (2) PT2889043T (enExample)
SI (2) SI2465542T1 (enExample)
SM (2) SMT201900375T1 (enExample)
TR (1) TR201909909T4 (enExample)
WO (1) WO2010075010A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107075468A (zh) * 2014-09-30 2017-08-18 阿米库斯治疗学公司 具有增强的碳水化合物的高强度酸性α‑葡糖苷酶

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
PT2121713E (pt) * 2007-01-18 2013-06-25 Genzyme Corp Oligossacáridos compreendendo um grupo aminooxi e seus conjugados
EP2465542B1 (en) 2008-12-16 2015-01-21 Genzyme Corporation Oligosaccharide-protein conjugates
PL2470199T3 (pl) 2009-08-28 2019-11-29 Icahn School Med Mount Sinai Enzymatyczna terapia zastępcza ze zwiększaniem dawki do leczenia niedoboru kwaśnej sfingomielinazy
BR112013026976A2 (pt) 2011-04-22 2019-09-24 Genzyme Corp alfa glucosidade ácida modificada com processamento acelerado
EP2793922B1 (en) * 2011-12-23 2019-10-30 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
JP6055466B2 (ja) * 2012-05-24 2016-12-27 国立大学法人 東京大学 酸化オリゴ糖で架橋したゲル材料
WO2016146760A1 (en) 2015-03-17 2016-09-22 Greenovation Biotech Gmbh Glycosylated lysosomal proteins, method of production and uses
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
CA3010205A1 (en) 2015-12-30 2017-07-06 Amicus Therapeutics, Inc. Augmented acid alpha-glucosidase for the treatment of pompe disease
JP6996676B2 (ja) * 2016-03-30 2022-02-04 国立研究開発法人農業・食品産業技術総合研究機構 マンノース－６－リン酸基含有糖蛋白質の製造方法、及び蛍光基結合型マンノース－６－リン酸基含有糖蛋白質の細胞内分布を検出する方法
MX2018011951A (es) 2016-03-30 2019-02-13 Amicus Therapeutics Inc Metodo para seleccionar proteinas recombinantes ricas en m6p.
IL301319A (en) 2016-03-30 2023-05-01 Amicus Therapeutics Inc Formulations that include recombinant acid alpha-glucosidase
BE1024634B1 (fr) * 2016-04-05 2018-05-14 Gsk Vaccines S.R.L. Compositions immunogenes
CN106432371A (zh) * 2016-10-31 2017-02-22 中国人民解放军第二军医大学 β‑1,2‑D‑寡聚甘露糖蛋白缀合物及其制备方法和应用
CN106366163A (zh) * 2016-10-31 2017-02-01 中国人民解放军第二军医大学 一种β‑1,2‑D‑寡聚甘露糖肽‑蛋白缀合物及其制备方法和应用
EP3624831B1 (en) 2017-05-15 2023-03-29 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase
AU2019300832B2 (en) 2018-07-09 2025-05-22 Merck Sharp & Dohme Llc Enzymatic synthesis of 4'-ethynyl nucleoside analogs
KR20210081324A (ko) 2018-08-02 2021-07-01 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
EP3897747A4 (en) * 2018-12-19 2022-12-07 The Board of Trustees of the Leland Stanford Junior University BIFUNCTIONAL MOLECULES FOR LYSOSOMA TARGETING AND RELATED COMPOSITIONS AND METHODS
IL295415A (en) * 2020-02-08 2022-10-01 Genzyme Corp Compositions and methods for treating pompe disease
WO2021257409A1 (en) 2020-06-14 2021-12-23 Genzyme Corporation Compositions and methods for treating late-onset pompe disease
EP4370157A1 (en) 2021-07-14 2024-05-22 Lycia Therapeutics, Inc. Asgpr cell surface receptor binding compounds and conjugates

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008089403A2 (en) * 2007-01-18 2008-07-24 Genzyme Corporation Oligosaccharides comprising an aminooxy group and conjugates thereof
WO2008089339A2 (en) * 2007-01-18 2008-07-24 Genzyme Corporation Oligosaccharide conjugates for cellular targeting

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4701521A (en) 1978-07-17 1987-10-20 The Trustees Of Boston University Method of effecting cellular uptake of molecules
US4749570A (en) 1981-12-31 1988-06-07 The Governors Of The University Of Alberta Targeting conjugates of albumin and therapeutic agents
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
JPS5936691A (ja) * 1982-08-24 1984-02-28 Rikagaku Kenkyusho 新規オリゴマンノシド及びその製造法
US5851991A (en) 1987-08-31 1998-12-22 The Regents Of The University Of California Therapeutic use of the retinoblastoma susceptibility gene product
US5066789A (en) 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
IL93432A (en) 1989-02-24 1994-02-27 Johnson Mathey Inc Hydrazines and hydrazides, their conjugates with macromolecules, and such conjugates labeled with metallic ions
US5206370A (en) 1989-02-24 1993-04-27 Johnson Matthey, Inc. Certain pyridyl hydrazines and hydrazides useful for protein labeling
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5212298A (en) 1989-08-16 1993-05-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
US5280113A (en) 1989-08-16 1994-01-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
US5324663A (en) 1990-02-14 1994-06-28 The Regents Of The University Of Michigan Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5583042A (en) 1990-04-16 1996-12-10 Neose Pharmaceuticals, Inc. Apparatus for the synthesis of saccharide compositions
US5312903A (en) * 1990-06-01 1994-05-17 E. I. Du Pont De Nemours And Company Lysine-glycosylated recombinant interleukin-2
US5677440A (en) 1990-07-16 1997-10-14 Howard Florey Institute Of Experimental Physiology And Medicine Oligonucleotide-polyamide conjugates
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2073511A1 (en) 1990-11-14 1992-05-29 Matthew R. Callstrom Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins
WO1992016555A1 (en) 1991-03-18 1992-10-01 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
RO111990B1 (ro) * 1991-12-20 1997-04-30 Novo Nordisk As Preparate farmaceutice, continand un hormon de crestere sau un derivat al acestuia, si procedeu de preparare
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
FR2721612B1 (fr) 1994-06-23 1996-08-09 Idm Nouveaux dérivés d'oligosides, leur procédé de préparation et leurs applications.
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5719131A (en) 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5767099A (en) 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US5948767A (en) 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US5939401A (en) 1994-12-09 1999-08-17 Genzyme Corporation Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
US5747471A (en) 1994-12-09 1998-05-05 Genzyme Corporation Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules
US5650096A (en) 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5910487A (en) 1994-12-09 1999-06-08 Genzyme Corporation Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
US6492332B1 (en) 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
US5811510A (en) 1995-04-14 1998-09-22 General Hospital Corporation Biodegradable polyacetal polymers and methods for their formation and use
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
ES2317646T3 (es) 1995-09-08 2009-04-16 Genzyme Corporation Vectores aav mejorados para terapia genica.
WO1997010817A1 (en) 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US7141676B1 (en) 1996-02-08 2006-11-28 University Of Washington Water soluble multi-biotin-containing compounds
CA2249323A1 (en) * 1996-03-21 1997-09-25 Transcell Technologies, Inc. Solid phase lipoglycopeptide library, compositions and methods
US5840702A (en) 1996-03-22 1998-11-24 Uab Research Foundation Cystic fibrosis treatment
US5935936A (en) 1996-06-03 1999-08-10 Genzyme Corporation Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
AUPO190596A0 (en) 1996-08-26 1996-09-19 Alchemia Pty Ltd Oligosaccharide synthesis
CA2265464C (en) 1996-09-13 2007-06-26 Transkaryotic Therapies, Inc. Therapy for .alpha.-galactosidase a deficiency
US5861397A (en) 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
EP0959905B1 (en) 1997-01-21 2009-12-09 Sanofi Pasteur Polysaccharide-peptide-conjugates
US5925628A (en) 1997-03-31 1999-07-20 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5912239A (en) 1997-04-04 1999-06-15 Genzyme Corporation Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
US5948925A (en) 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US5952516A (en) 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
US5942634A (en) 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
EP2147681A1 (en) 1997-10-29 2010-01-27 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
SE513149C2 (sv) 1997-12-05 2000-07-17 Katarina Edwards Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6703488B1 (en) 1998-01-15 2004-03-09 Center For Molecular Medicine And Immunology Antibody/receptor targeting moiety for enhanced delivery of armed ligand
US6287857B1 (en) 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
EP1054989A1 (en) 1998-02-17 2000-11-29 Genzyme Corporation Methods for pseudoadenoviral vector production
WO1999041399A1 (en) 1998-02-17 1999-08-19 Genzyme Corporation Methods for purified aav vector production
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
WO1999057296A1 (en) 1998-05-01 1999-11-11 Genzyme Corporation Partially deleted adenoviral vectors
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6538117B1 (en) 1999-08-10 2003-03-25 The Scripps Research Institute Programmable one-pot oligosaccharide synthesis
US6399575B1 (en) 1998-11-10 2002-06-04 Auburn University Methods and compositions for targeting compounds to the central nervous system
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
GB9909066D0 (en) 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
GB9909064D0 (en) 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
EP1196190B1 (en) 1999-07-26 2003-03-19 G.D. SEARLE & CO. Use of long-chain n-alkyl derivatives of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of a medicament for the treatment of glycolipid storage diseases
US6770468B1 (en) 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
ATE360082T1 (de) 1999-11-16 2007-05-15 Genzyme Corp Vektoren und transgene mit regulatorischen elementen zur genverabreichung in leber
IL151024A0 (en) 2000-02-15 2003-02-12 Genzyme Corp Conjugates of a biopolymer and a therapeutic agent
US6749865B2 (en) 2000-02-15 2004-06-15 Genzyme Corporation Modification of biopolymers for improved drug delivery
AU2001236713A1 (en) 2000-02-17 2001-08-27 Genzyme Corporation Methods for treatment of lysosomal storage diseases
WO2002057445A1 (en) 2000-05-26 2002-07-25 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US20040014652A1 (en) 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same
WO2001097829A2 (en) 2000-06-19 2001-12-27 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
AU2001280035A1 (en) 2000-07-26 2002-02-05 Ramot University Authority For Applied Research And Industrial Development Ltd. Intracellular delivery system for protein phosphatases and other polypeptides
JP2004507467A (ja) 2000-08-18 2004-03-11 マサチューセッツ　インスティテュート　オブ　テクノロジー オリゴ糖の自動化合成のための装置及び方法
US6676963B1 (en) 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
ES2300439T3 (es) 2001-04-30 2008-06-16 Zystor Therapeutics , Inc. Reconocimiento subcelular de proteinas terapeuticas.
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2001090139A2 (en) 2001-05-07 2001-11-29 Supratek Pharma Inc. A ligand for enhancing oral and cns delivery of biological agents
CA2453978C (en) 2001-07-16 2011-10-11 Genzyme Corporation Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
CA2462930C (en) 2001-10-10 2012-07-10 Shawn De Frees Remodeling and glycoconjugation of peptides
AU2002348261A1 (en) 2001-11-26 2003-06-10 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
EP1461445B1 (en) 2001-11-28 2008-08-20 Neose Technologies, Inc. Glycoprotein remodeling using endoglycanases
US6800472B2 (en) 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
US6905856B2 (en) 2001-12-21 2005-06-14 Genzyme Glycobiology Research Institute, Inc. Soluble GlcNAc phosphotransferase
ES2496493T3 (es) 2002-01-11 2014-09-19 Bioasis Technologies Inc. Uso de p97 como sistema de administración de enzimas para la administración de enzimas lisosómicas terapéuticas
DE60329126D1 (de) 2002-02-20 2009-10-15 Beth Israel Hospital Konjugate mit biologisch abbaubarem polymer und verwendung dafür
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
WO2004069190A2 (en) 2003-01-31 2004-08-19 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiency disorders
EP1638605B1 (en) 2003-06-20 2014-01-08 Raptor Pharmaceutical, Inc. Delivery of therapeutic compounds to the brain and other tissues
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
EP1654004A2 (en) 2003-08-08 2006-05-10 Novo Nordisk A/S Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
EP1654289B1 (en) 2003-08-12 2007-10-03 Lipoxen Technologies Limited Polysialic acid derivatives
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US7232805B2 (en) 2003-09-10 2007-06-19 Inflabloc Pharmaceuticals, Inc. Cobalamin conjugates for anti-tumor therapy
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
US7176185B2 (en) 2003-11-25 2007-02-13 Tsrl, Inc. Short peptide carrier system for cellular delivery of agent
JP2007519746A (ja) 2004-01-29 2007-07-19 バイオシネクサス インコーポレーティッド ワクチン調製におけるアミノ−オキシ官能基の使用
CA2556245A1 (en) 2004-02-06 2005-08-25 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
SI1740204T1 (en) 2004-04-01 2018-07-31 Chiesi Farmaceutici S.P.A. MEDICAL APPLICATION OF ALFA-MANOSIDES
US8017151B2 (en) 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
JP5137814B2 (ja) 2005-04-06 2013-02-06 ジェンザイム・コーポレーション 治療ターゲティングのための酸不安定リンカーを介するｐｅｇおよびポリシアルリソソーム酵素のコンジュゲート
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
EP2623610B1 (en) * 2006-02-10 2015-04-29 Life Technologies Corporation Labeling and detection of post translationally modified proteins
EP2465542B1 (en) 2008-12-16 2015-01-21 Genzyme Corporation Oligosaccharide-protein conjugates
US12285108B1 (en) 2024-08-08 2025-04-29 Frank R. Connors Shelf device with interchangeable faceplate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008089403A2 (en) * 2007-01-18 2008-07-24 Genzyme Corporation Oligosaccharides comprising an aminooxy group and conjugates thereof
WO2008089339A2 (en) * 2007-01-18 2008-07-24 Genzyme Corporation Oligosaccharide conjugates for cellular targeting

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BYT. BRUCEG RINDLEY: "Applications of tin-containing intermediates to carbohydrate chemistry", 《ADVANCES IN CARBOHYDRATE CHEMISTRY AND BIOCHEMISTRY》 *
TAMIO SUGAWARA 等: "Synthesis of ω-( methoxycarbonyl) alkyl and 9-( methoxycarbonyl)-3,6-dioxanonyl glycopyranosides for the preparation of carbohydrate-protein conjugates", 《CARBOHYDRATE RESEARCH》 *
VINAI K. SRIVASTAVA 等: "synthesis of β-D-mannopyranosides and regioselective O-alkylation of dibutylstannylene complexes", 《TETRAHEDRON LETTERS》 *
YUNXIANG ZHU等: "Carbohydrate-remodelled acid α-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice", 《BIOCHEM. J.》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107075468A (zh) * 2014-09-30 2017-08-18 阿米库斯治疗学公司 具有增强的碳水化合物的高强度酸性α‑葡糖苷酶
CN107075468B (zh) * 2014-09-30 2021-12-24 阿米库斯治疗学公司 具有增强的碳水化合物的高强度酸性α-葡糖苷酶

Also Published As

Publication number Publication date
DK2465542T3 (en) 2015-04-27
BRPI0923047B8 (pt) 2021-05-25
ES2937017T3 (es) 2023-03-23
EP3608330A3 (en) 2020-05-13
MX2011006347A (es) 2011-09-06
US8835614B2 (en) 2014-09-16
US11279725B2 (en) 2022-03-22
JP2023164869A (ja) 2023-11-14
EP2889043A3 (en) 2015-07-22
IL237932B (en) 2019-12-31
US20220242899A1 (en) 2022-08-04
US20150175643A1 (en) 2015-06-25
US20200216485A1 (en) 2020-07-09
WO2010075010A3 (en) 2011-01-06
MX364498B (es) 2019-04-29
HUE044381T2 (hu) 2019-10-28
CA2747230C (en) 2019-06-11
JP7590515B2 (ja) 2024-11-26
IL270930A (en) 2020-01-30
PT2889043T (pt) 2019-07-16
LT2889043T (lt) 2019-07-10
JP5658167B2 (ja) 2015-01-21
EP3608330B1 (en) 2022-11-09
IL213595B (en) 2018-02-28
HRP20191102T1 (hr) 2019-09-20
CA2747230A1 (en) 2010-07-01
CY1121860T1 (el) 2020-07-31
EP3608330A2 (en) 2020-02-12
EP4212541A1 (en) 2023-07-19
CA3040973A1 (en) 2010-07-01
US20180002365A1 (en) 2018-01-04
SI2889043T1 (sl) 2019-08-30
EP2376123A2 (en) 2011-10-19
HK1171697A1 (en) 2013-04-05
IL284184B2 (en) 2023-06-01
CN103432566A (zh) 2013-12-11
EP2889043B1 (en) 2019-04-10
ES2534056T3 (es) 2015-04-17
IL213595A0 (en) 2011-07-31
US10464962B2 (en) 2019-11-05
WO2010075010A2 (en) 2010-07-01
US20110300120A1 (en) 2011-12-08
JP2012512313A (ja) 2012-05-31
BRPI0923047A2 (pt) 2015-12-08
CN112618724A (zh) 2021-04-09
EP2465542B1 (en) 2015-01-21
IL270930B (en) 2021-07-29
HUE060974T2 (hu) 2023-04-28
MX2019004905A (es) 2020-11-12
JP2021169467A (ja) 2021-10-28
DK2889043T3 (da) 2019-07-15
BR122020010601B1 (pt) 2021-02-23
US12252504B2 (en) 2025-03-18
CN112220930A (zh) 2021-01-15
EP2889043A2 (en) 2015-07-01
SMT201500082B (it) 2015-07-09
SI2465542T1 (sl) 2015-05-29
JP2014139204A (ja) 2014-07-31
PL2889043T3 (pl) 2019-09-30
DK3608330T3 (da) 2023-02-06
JP2019112444A (ja) 2019-07-11
US9493498B2 (en) 2016-11-15
HRP20150340T1 (hr) 2015-07-31
PL2465542T3 (pl) 2015-06-30
IL284184A (en) 2021-07-29
IL237933A0 (en) 2015-05-31
PT2465542E (pt) 2015-04-16
EP2465542A1 (en) 2012-06-20
TR201909909T4 (tr) 2019-07-22
SMT201900375T1 (it) 2019-09-09
ES2735023T3 (es) 2019-12-13
JP6659503B2 (ja) 2020-03-04
CN105879047A (zh) 2016-08-24
BR122020010601B8 (pt) 2021-07-27
IL237932A0 (en) 2015-05-31
BRPI0923047B1 (pt) 2020-11-24
JP2017008098A (ja) 2017-01-12
HK1210413A1 (en) 2016-04-22

Similar Documents

Publication Publication Date Title
JP7590515B2 (ja) オリゴ糖－タンパク複合体
HK40096824A (en) Oligosaccharide-protein conjugates and their intermediates
HK40020087B (en) Synthetic intermediates for preparing oligosaccharide-protein conjugates
HK40020087A (en) Synthetic intermediates for preparing oligosaccharide-protein conjugates
HK1168024A (en) Oligosaccharide-protein conjugates
HK1210413B (en) Synthetic intermediates for preparing oligosaccharide-protein conjugates
HK1171697B (en) Oligosaccharide-protein conjugates

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1168024

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120307